-- Durable disease control and quality-of-life improvements for patients with ISM in the PIONEER trial -- -- Prolonged survival, including in the first-line treatment setting, for patients with ...
Get any of our free daily email newsletters — news headlines, opinion, e-edition, obituaries and more. Ghassane Moutaoukil, a Montana State University graphic design graduate, has found himself in the ...
William & Mary's Graduate Center invites graduate students conducting research in Humanities, Humanistic Social Sciences, and the Sciences to present at the upcoming Graduate Research Symposium.
– Axatilimab abstracts highlight potential for long-term benefit in R/R chronic GVHD and tolerability of axatilimab with ruxolitinib in newly diagnosed chronic GVHD – “The breadth of the upcoming data ...
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase ...
SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present ...
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with ...
The submission website supports the latest version of Chrome, the current and previous release of Firefox, Safari and Microsoft browsers. Cookies and JavaScript must be enabled. You must submit your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback